Investment Thesis
Telomir is a pre-revenue pharmaceutical development company with an annual operating cash burn of $1.8M, approximately 3 years of cash runway remaining. Despite improving loss metrics year-over-year, fundamental viability cannot be established without demonstrable product commercialization or revenue generation.
Strengths
- Strong cash position relative to burn rate ($5.6M cash with $1.8M annual burn)
- Improving loss metrics (37% YoY improvement in net loss, 41% improvement in EPS)
- Minimal debt burden (0.02x Debt/Equity) provides financial flexibility
Risks
- Pre-revenue company with no demonstrated commercial viability or revenue generation
- Negative returns on equity (-20%) and assets (-17%) indicate shareholder value destruction
- Unsustainable cash burn will deplete resources within approximately 3 years without revenue achievement
- High execution risk inherent to drug development (regulatory approval, clinical success probability unknown)
Key Metrics to Watch
- Revenue achievement and growth trajectory
- Operating cash flow burn rate and path to sustainability
- Cash runway in months remaining
- Pipeline advancement (clinical trial results, regulatory milestone achievements)
Financial Metrics
Revenue
N/A
Net Income
-990.9K
EPS (Diluted)
$-0.03
Free Cash Flow
-1.8M
Total Assets
5.8M
Cash
5.6M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-20.0%
ROA
-17.1%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
7.00x
Quick Ratio
7.00x
Debt/Equity
0.02x
Debt/Assets
14.3%
Interest Coverage
0.50x
Long-term Debt
100.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T10:13:54.152563 |
Data as of: 2026-03-31 |
Powered by Claude AI